ArticleBMJ open2022
Biomarker identification using dynamic time warping analysis: a longitudinal cohort study of patients with COVID-19 in a UK tertiary hospital.
Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Full blood count dynamics in immunologically naïve individuals with mild COVID-19: A prospective community cohort study.PloS one · 2026Article
- The Role of Serial Monitoring of Laboratory Parameters in Determining the Need for Intensive Care in Severe COVID-19: A Single-Center Retrospective Study.Infectious diseases & clinical microbiology · 2025Article
- Chest computed tomography and plain radiographs demonstrate vascular distribution and characteristics in COVID-19 lung disease - a pulmonary vasculopathy.The Ulster medical journal · 2025Article
- Hidden in plain sight: the impact of human rhinovirus infection in adults.Respiratory research · 2025Review
- Study of Biochemical Parameters as Predictors for Need of Invasive Ventilation in Severely Ill COVID-19 Patients.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2023Article
- Characterising biological mechanisms underlying ethnicity-associated outcomes in COVID-19 through biomarker trajectories: a multicentre registry analysis.British journal of anaesthesia · 2023Article
- Comparison of time series clustering methods for identifying novel subphenotypes of patients with infection.Journal of the American Medical Informatics Association : JAMIA · 2023Article
- On-admission and dynamic trend of laboratory profiles as prognostic biomarkers in COVID-19 inpatients.Scientific reports · 2023Article
- Assessing the communication gap between AI models and healthcare professionals: Explainability, utility and trust in AI-driven clinical decision-making.Artificial intelligence · 2023Article
- Vascular risk factors for COVID-19 ARDS: endothelium, contact-kinin system.Frontiers in medicine · 2023Review
- Biochemical and hematological factors associated with COVID-19 severity among Gabonese patients: A retrospective cohort study.Frontiers in cellular and infection microbiology · 2022Article
- Wave comparisons of clinical characteristics and outcomes of COVID-19 admissions - Exploring the impact of treatment and strain dynamics.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022Observational
- Dysregulation of COVID-19 related gene expression in the COPD lung.Respiratory research · 2021Article
- Digital healthcare in COPD management: a narrative review on the advantages, pitfalls, and need for further research.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesCOVID-19 is a heterogeneous disease, and many reports have described variations in demographic, biochemical and clinical features at presentation influencing overall hospital mortality. However, there is little information regarding longitudinal changes in laboratory prognostic variables in relation to disease progression in hospitalised patients with COVID-19. DESIGN AND
settingThis retrospective observational report describes disease progression from symptom onset, to admission to hospital, clinical response and discharge/death among patients with COVID-19 at a tertiary centre in South East England.
participantsSix hundred and fifty-one patients treated for SARS-CoV-2 between March and September 2020 were included in this analysis. Ethical approval was obtained from the HRA Specific Review Board (REC 20/HRA/2986) for waiver of informed consent.
resultsThe majority of patients presented within 1 week of symptom onset. The lowest risk patients had low mortality (1/45, 2%), and most were discharged within 1 week after admission (30/45, 67%). The highest risk patients, as determined by the 4C mortality score predictor, had high mortality (27/29, 93%), with most dying within 1 week after admission (22/29, 76%). Consistent with previous reports, most patients presented with high levels of C reactive protein (CRP) (67% of patients >50 mg/L), D-dimer (98%>upper limit of normal (ULN)), ferritin (65%>ULN), lactate dehydrogenase (90%>ULN) and low lymphocyte counts (81%<lower limit of normal (LLN)). Increases in platelet counts and decreases in CRP, neutrophil:lymphocyte ratio (p<0.001), lactate dehydrogenase, neutrophil counts, urea and white cell counts (all p<0.01) were each associated with discharge.
conclusionsSerial measurement of routine blood tests may be a useful prognostic tool for monitoring treatment response in hospitalised patients with COVID-19. Changes in other biochemical parameters often included in a 'COVID-19 bundle' did not show significant association with outcome, suggesting there may be limited clinical benefit of serial sampling. This may have direct clinical utility in the context of escalating healthcare costs of the pandemic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.